

Supplementary Appendix 1

Full reference list (ISPOR ABSTRACT ID: 133178)

1. Ascierto PA, Del Vecchio M, Mackiewicz A, Robert C, Chiarion-Sileni V, Arance A, et al. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. *J Immunother Cancer*. 2020;8(1):e000391.
2. Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. *JAMA Oncol*. 2019;5(2):187-194.
3. Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134. *J Clin Oncol*. 2023;41(2):186-197.
4. Hodi FS, Tawbi HA, Lipson EJ, Schadendorf D., Ascierto PA, Matamala LA, et al. 817P Nivolumab (NIVO)+ relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047. *Ann Oncol*. 2022;33(7): S920-S921.
5. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *New Engl J Med*. 2019;381:1535-1546.
6. Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. *Lancet*. 2022;400(10358):1117-1129.
7. Long GV, Schachter J, Arance A, Grob J-J, Mortier L, Daud A, et al. Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma. *J Clin Oncol*. 2020;38(15_suppl):10013.
8. Mandala M, Larkin J, Ascierto PA, Del Vecchio M, Gogas H, Cowey CL, et al. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. *J Immunother Cancer*. 2021;9(8):e003188
9. Namikawa K, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, Yoshikawa S, et al. Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naïve advanced melanoma. *J Dermatol*. 2020;47(11):1257-1266.
10. Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. *J Clin Oncol*. 2020;38(33):3937-3946.
11. Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, et al. 1082MO 5-year characterization of complete responses in patients with

advanced melanoma who received nivolumab plus ipilimumab (NIVO+ IPI) or NIVO alone. *Ann Oncol*. 2020;31:S734-S735.

12. Robert C, Schachter J, Long GV, Arance A, Grob J-J, Mortier L, et al. Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naïve advanced melanoma. *Cancer Res*. 2019;79(13_Supplement):CT188.
13. Uhara H, Kiyohara Y, Uehara J, Fujisawa Y, Takenouchi T, Otsuka M, et al. Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. *J Dermatol*. 2021;48(5):592-599.
14. Weber JS, Larkin J, Del Vecchio M, Mandala M, Gogas H, Fernandez AMA, et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. *Clin Cancer Research*. 2023;OF1-OF10.
15. Weber J, Del Vecchio M, Mandala M, Gogas H, Fernandez AMA, Dalle S, et al. 1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. *Ann Oncol*. 2020;31(4):S731-S732.
16. Weber JS, Poretti T, Stwalley BD, Sakkal LA, Du EX, Wang T, et al. Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. *Cancer Immunol Immunother*. 2023;72(4):955.
17. Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). *J Clin Oncol*. 2023;41(3):517-527.
18. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. *J Clin Oncol*. 2022;40(2):127-137.
19. Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020;395(10236):1558-1568.
20. NICE. Technology appraisal guidance [TA357]: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab; October 2015 [updated 12 September 2017]. Available from: <https://www.nice.org.uk/guidance/ta357/chapter/1-Guidance>
21. NICE. Technology appraisal guidance [TA366]. Pembrolizumab for advanced melanoma not previously treated with ipilimumab; November 2015. [updated 12 September 2017]. Available from: <https://www.nice.org.uk/guidance/ta366/chapter/1-Guidance>

22. NICE. Technology appraisal guidance [TA766]. Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma; February 2022. Available from: <https://www.nice.org.uk/guidance/ta766>
23. NICE. Technology appraisal guidance [TA837]. Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma; October 2022. Available from: <https://www.nice.org.uk/guidance/TA837>
24. NICE. Technology appraisal guidance [TA400]. Nivolumab in combination with ipilimumab for treating advanced melanoma; July 2016. Available from: <https://www.nice.org.uk/guidance/ta400>
25. NICE. Technology appraisal guidance [TA384]. Nivolumab for treating advanced (unresectable or metastatic) melanoma; February 2016. Available from: <https://www.nice.org.uk/guidance/ta384>
26. NICE. Technology appraisal guidance [TA684]. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease; March 2021. Available from: <https://www.nice.org.uk/guidance/ta684>
27. NICE. Technology appraisal guidance [TA319]. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma; July 2014. Available from: <https://www.nice.org.uk/guidance/ta319>
28. NICE. Technology appraisal guidance [TA268]. Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma; December 2012. Available from: <https://www.nice.org.uk/guidance/ta268>
29. Ipilimumab Public Summary Document: Bristol Myers Squibb Australia Pty Ltd; November 2012. Available from: <https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2012-11/ipilimumab>
30. Ipilimumab Public Summary Document (PBAC Meeting): Bristol-Myers Squibb Australia Pty Ltd; July 2016. Available from: <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-07/files/ipilimumab-psd-july-2016.pdf>
31. Nivolumab Plus Ipilimumab Public Summary Document (PBAC Meeting): Bristol-Myers Squibb Australia Pty Ltd; July 2018. Available from: <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2018-07/files/nivolumab-and-ipilimumab-melanoma-psd-july-2018.pdf>
32. Nivolumab Plus Ipilimumab Public Summary Document (PBAC Meeting): Bristol-Myers Squibb Australia Pty Ltd; November 2022. Available from: <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2022-11/files/nivolumab-and-ipilimumab-psd-11-2022.pdf>
33. Nivolumab Plus ipilimumab Public Summary Document (PBAC Meeting): Bristol-Myers Squibb Australia Pty Ltd; March 2017. Available from: <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2017-03/files/nivolumab-and-ipilimumab-psd-march-2017.pdf>

34. Nivolumab Public Summary Document (PBAC Meeting): Bristol-Myers Squibb Australia Pty Ltd; November 2015. Available from:
<https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2015-11/files/nivolumab-psd-november-2015.pdf>
35. Nivolumab Public Summary Document (PBAC Meeting): Bristol-Myers Squibb Australia Pty Ltd; July 2018. Available from:
<https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2018-07/files/nivolumab-melanoma-psd-july-2018.pdf>
36. Nivolumab(a) Public Summary Document (PBAC Meeting): Bristol-Myers Squibb Australia Pty Ltd; March 2019. Available from:
<https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-03/files/nivolumab-melanoma-psd-march-2019.pdf>
37. Nivolumab(b) Public Summary Document (PBAC Meeting): Bristol-Myers Squibb Australia Pty Ltd; March 2019. Available from:
<https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2019-03/nivolumab-melanoma-psd-march-2019>
38. Nivolumab Public Summary Document (PBAC Meeting): Bristol-Myers Squibb Australia Pty Ltd; July 2019. Available from:
<https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-07/files/nivolumab-psd-july-2019.pdf>
39. Nivolumab Public Summary Document (PBAC Meeting): Bristol-Myers Squibb Australia Pty Ltd; November 2019. Available from:
<https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-11/files/nivolumab-psd-november-2019.pdf>
40. Pembrolizumab Public Summary Document (PBAC Meeting): Merck Sharpe & Dohme (Australia) Pty Ltd; March 2015. Available from:
<https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2015-03/Files/pembrolizumab-psd-march-2015.pdf>
41. Pembrolizumab Public Summary Document (PBAC Meeting): Merck Sharpe & Dohme (Australia) Pty Ltd; November 2016. Available from:
<https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-11/files/pembrolizumab-melanoma-psd-november-2016.pdf>
42. Pembrolizumab Public Summary Document (PBAC Meeting): Merck Sharpe & Dohme (Australia) Pty Ltd; March 2018. Available from:
<https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2018-03/files/pembrolizumab-dosing-psd-march-2018.pdf>
43. Pembrolizumab Public Summary Document (PBAC Meeting): Merck Sharpe & Dohme (Australia) Pty Ltd; November 2018. Available from:
<https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2018-11/files/pembrolizumab-melanoma-psd-november-2018.pdf>
44. Pembrolizumab Public Summary Document (PBAC Meeting): Merck Sharpe & Dohme (Australia) Pty Ltd; July 2019. Available from:
<https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-07/files/pembrolizumab-melanoma-psd-july-2019.pdf>

45. Pembrolizumab Public Summary Document (PBAC Minutes): Merck Sharpe & Dohme (Australia) Pty Ltd; November 2019. Available from: <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-11/files/pembrolizumab-psd-november-2019.pdf>
46. Pembrolizumab (melanoma resubmission) Public Summary Document; March 2020. Available from: <https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2020-03/pembrolizumab-melanoma-resubmission-solution-concentrate>
47. Pembrolizumab (malignant melanoma) Public Summary Document (PBAC Meeting): Merck Sharpe & Dohme (Australia) Pty Ltd; March 2020. Available from: <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2020-03/files/pembrolizumab-melanoma-psd-march-2020.pdf>
48. Pembrolizumab (malignant melanoma and non-small cell lung cancer) Public Summary Document (PBAC Meeting): Merck Sharpe & Dohme (Australia) Pty Ltd; March 2020. Available from: <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2020-03/files/pembrolizumab-melanoma-nsccl-psd-march-2020.pdf>